Ahmad Vafaeian

Ahmad Vafaeian

Auto-generated profile, based on publicly available information

Ahmad Vafaeian

Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Heliyon
Verified
Journal Article
Open access
AVAhmad Vafaeian
Ahmad Vafaeian
FRFateme Rajabi
Fateme Rajabi
NRNima Rezaei
Nima Rezaei
Toll-like receptors (TLR), the key players of the innate immune system, contribute to the pathogenesis of atopic dermatitis (AD) through multiple pathways. TLRs play a crucial role in delaying barrier repair, promoting Th2-mediated dermatitis, shifting the response toward Th1 in the chronic phase, and contributing to the establishment of the itch-scratch cycle, as well as mediating the effects of UV radiation. The dysregulation of proinflammatory and immunomodulatory effects of TLRs can be attributed to their ligand structures, receptor heterodimerization, the relative frequency of each TLR, interactions with other receptors/signalling pathways, cytokine milieu, and genetic polymorphisms. Current AD treatments like vitamin-D analogs, tacrolimus, and cyclosporine partially work through TLR modulation. Direct TLR stimulation using different compounds has shown therapeutic benefits in preclinical studies. However, significant challenges exist, including off-target effects due to ubiquitous TLR expression and complex roles in immune responses. Future directions include CRISPR-based gene editing to understand TLR functions, development of specific TLR modulators for targeted therapy, and machine learning applications to predict drug responses and identify novel ligands. Patient heterogeneity, including the presence or absence of polymorphisms, variations in TLR expression levels, and differences in immune responses, underscores the need for personalized therapeutic approaches.

20 September 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
AVAli Vafaei
Ali Vafaei
AVAhmad Vafaeian
Ahmad Vafaeian
AIArad Iranmehr
Arad Iranmehr
ENEhsan Nassireslami
Ehsan Nassireslami
BHBehnam Hasannezhad
Behnam Hasannezhad
YHYasaman Hosseini
Yasaman Hosseini
Aims: Anxiety often coexists with migraine, and both conditions share a commonality in oxidative/nitrosative stress and mitochondrial dysfunction contributing to their pathogenesis. β‐Sitosterol, a plant sterol, has shown promise in mitigating oxidative/nitrosative stress, enhancing mitochondrial function, and exerting neuroprotective effects. In this study, we investigated the impact of β‐sitosterol on migraine‐associated anxiety and whether this effect was associated with alleviation of oxidative/nitrosative stress and improvement in mitochondrial function.Methods: Nitroglycerin was used to induce migraine in adult male Wistar rats. β‐Sitosterol treatment consisted of daily intraperitoneal injections (10 mg/kg) for 10 days following migraine induction. Anxiety levels were evaluated using open‐field test (OFT) and hole‐board test (HBT). Frontal cortex samples were analyzed for malondialdehyde (MDA), glutathione (GSH), reactive oxygen/nitrogen species, nitric oxide (NO) (markers of oxidative/nitrosative stress), and ATP (indicator of mitochondrial function).Results: Migraine induction led to impaired performance in both the OFT and the HBT. Concurrently, it elevated MDA, reactive oxygen/nitrogen species, and NO levels while diminishing GSH levels in the frontal cortex, signifying heightened oxidative/nitrosative stress. Moreover, ATP levels decreased, indicating mitochondrial dysfunction. Treatment with β‐sitosterol significantly restored performance in both behavioral assays and normalized the levels of MDA, GSH, reactive oxygen/nitrogen species, NO, and ATP.Conclusion: β‐Sitosterol exerted anxiolytic effects in migraine, which can be attributed to its ability to ameliorate oxidative/nitrosative stress and enhance mitochondrial function.

4 February 2025 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
AVAhmad Vafaeian
Ahmad Vafaeian
AVAli Vafaei
Ali Vafaei
MPMohammad Reza Parvizi
Mohammad Reza Parvizi
MCMohsen Chamanara
Mohsen Chamanara
MMMojgan Mehriardestani
Mojgan Mehriardestani
YHYasaman Hosseini
Yasaman Hosseini
Migraine, a common disorder marked by severe and repetitive headaches, has been linked to the involvement of the NMDA receptor (NMDAR), a receptor responsible for glutamate signaling. Moringa oleifera (M. oleifera), recognized for its anti-inflammatory properties and therapeutic potential in various conditions, has been investigated. This study aims to assess the efficacy and precise mechanisms of M. oleifera for the treatment of migraine, for which evidence is limited. Rats were stratified into four distinct groups. The control group did not undergo the migraine-induction protocol. Post-induction, the “sumatriptan” group was administered sumatriptan injections, the “treatment” group received oral M. oleifera extract, and the “vehicle” group was provided with oral solvent treatment. Behavioral evaluations encompassing Von Frey’s and hot plate assessments, in addition to qPCR analysis targeting Nr2a, Nr2b, Bax, Bcl-2, and Caspase-3, were conducted. Von Fery’s and hot plate tests revealed a notable decrease in triggering pressure and temperature within the vehicle group when compared to the other groups (both ps < 0.001). The Nr2a expression levels in both the vehicle and treatment cohorts exhibited significantly higher values than those observed in the control group (p < 0.001, p = 0.001) and the sumatriptan group (p < 0.001, p = 0.002). Conversely, no substantial alterations in Nr2b or Bcl-2 expression levels were observed across the study groups (p = 0.404, p = 0.976). Notably, heightened expressions of Caspase-3 and Bax were evident in the vehicle group relative to the other groups (p = 0.013, p = 0.010). Moringa oleifera extract appears to mitigate symptoms of migraine by inhibiting apoptosis, suggesting potential efficacy in migraine treatment; however, additional research investigating a wider range of pathways is necessary. Not applicable.

7 February 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
ZDZeinab Dalvand
Zeinab Dalvand
AVAhmad Vafaeian
Ahmad Vafaeian
KBKamran Balighi
Kamran Balighi
HMHamidreza Mahmoudi
Hamidreza Mahmoudi
SDShayan Dasdar
Shayan Dasdar
MDMaryam Daneshpazhooh
Maryam Daneshpazhooh

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
AGAmirmansoor Gholami
Amirmansoor Gholami
AVAhmad Vafaeian
Ahmad Vafaeian
MDMaryam Daneshpazhooh
Maryam Daneshpazhooh
IEIfa Etesami
Ifa Etesami
KBKamran Balighi
Kamran Balighi
HMHamidreza Mahmoudi
Hamidreza Mahmoudi
Background. Treatment resistance to biologic treatment at specific sites in the body is a challenging issue. However, there is insufficient evidence for factors affecting the resistance of these areas to biological therapies. Methods. In this study, patients with moderate‐to‐severetreatment‐resistant psoriasis who were biologic naïve and referred to Razi hospital were included. The relationship between treatment resistance in different areas and demographic and clinical variables was investigated. Results. A total of 131 biologic‐naïve patients with psoriasis treated with anti‐TNF‐α were included in this study. The most common resistant sites included the scalp, anterior lower legs, and elbows. Also, hand‐ and toe‐nail involvements were considerable. BMI, gender, smoking, PASI score, the duration of the disease, the time distance between diagnosis and treatment, and treatment regiments were found to affect the incidence of resistance to treatment in multiple areas, while age, the incidence of recalcitrant disease and/or psoriatic arthritis, and the duration of current treatment did not have effects. Conclusion. The most common refractory sites were the scalp, anterior lower legs, and elbows. This study should be followed up with larger samples containing a variety of biological treatments in order to evaluate the results.

23 March 2023 in International Journal of Dermatology
Verified
Journal Article
Closed access
AVAhmad Vafaeian
Ahmad Vafaeian
AGArefeh Ghanbarzadeh
Arefeh Ghanbarzadeh
MDMaryam Daneshpazhooh
Maryam Daneshpazhooh
RARobabeh Abedini
Robabeh Abedini
KBKamran Balighi
Kamran Balighi
HMHamidreza Mahmoudi
Hamidreza Mahmoudi